Crimson Publishers Publish With Us Reprints e-Books Video articles

Full Text

Interventions in Obesity & Diabetes

Apolipoprotein A-V Genetic Variants in Obese Children

Guanghua Luo*

Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, China

*Corresponding author: Guanghua Luo, Comprehensive Laboratory, Changzhou Key Lab of Individualized Diagnosis and Treatment Associated with High Technology Research, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China

Submission: February 26, 2018; Published: March 05, 2018

DOI: 10.31031/IOD.2018.01.000511

ISSN: 2578-0263
Volume1 Issue3


Apolipoprotein A-V (APOA5) gene located on human 11q23 is an important determinant of plasma triglyceride levels [1]. Obese children with hyperinsulinemia had higher triglyceride (TG) level and lower APOA5 level than those without hyperinsulinemia and serum APOA5 was correlated negatively with TG level [2]. Single nucleotide polymorphisms (SNPs) of APOA5 were found to be significantly associated with plasma/serum TG levels in children [3-7]. SNP3 (ss3199915, now merged into rs662799) of APOA5 gene was found to play an important role in the variation of serum TG levels. The serum TG levels of the subjects with C allele were significantly higher than those ofthe subjects with the T/T genotype. The TG levels of the subjects with the T/C and C/C genotype were 12.7% and 31.8% higher than those of the subjects with the T/T genotype, respectively [3]. Horvatovich et al [4] examined four SNPs including T-1131C (rs662799), IVS3+G476A (rs2072560), T1259C (rs2266788) and C56G (rs3135506) of APOA5 and studied the frequencies of APOA5 haplotypes including APOA5*1 (TGTC), APOA5*2 (CACC), APOA5*3 (TGTG), APOA5*4 (CGTC) and APOA5*5 (TGCC) in obese children [4]. The results indicated that the prevalence of the APOA5*2 was about 2.59-fold increase while that of the APOA5*5 displayed 3.88-fold decrease in obese subjects compared with healthy children. Accordingly, carrying APOA5*2 and APOA5*4 haplotype variants resulted in a significant increase in serum TG levels, while the APOA5*5 haplotype had a serum TG level-decreasing. In Chinese child population, C carriers in rs662799 and rs651821 had 1.496-fold and 1.515-fold higher risk for developing obesity or overweight than those with T/T genotype. TG concentration was also significantly different among rs662799 variants [7]. SNP (rs778114184), the Arg282Ser missense mutation of APOA5 gene resulted in a significant reduction in serum APOA5 levels in heterozygous children and was associated with a significant reduction of TG levels in overweight/obese children [6]. Recently, a novel insertion polymorphism, c.*282-283 ins AG/c.*282-283 ins G-variant was identified in 3 UTR of APOA5 gene. And the presence of the AG insertion was associated with higher metabolic syndrome risk [5].

In summary, APOA5 is a regulator of serum TG. SNPs of APOA5 gene appear to be genetic risk factors for hypertriglyceridemia, and therefore increase obesity risk in children. The associations between variants in APOA5 gene and obese children need further study to improve the understanding of biological functions of APOA5 gene variants. In above studies, genotyping of SNPs was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis [3,4], PCR-direct sequencing method [5], PCR-high resolution melting analysis [6] and MassArray [7]. Here, I recommend a method named base- quenched probe [8] which is now available for detecting multimutations simultaneously in one tube [9].


  1. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, et al. (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294(5540): 169-173.
  2. Yoshino Y, Okada T, Abe Y, Odaka M, Kuromori Y, et al. (2013) Apolipoprotein A-V level may contribute to the development of obesity- associated dyslipidemia. Obes Res Clin Pract 7(5): e415-419.
  3. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, et al. (2002) Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 111(6): 570-572.
  4. Horvatovich K, Bokor S, Barath A, Maasz A, Kisfali P et al. (2011) Haplotype analysis of the apolipoprotein A5 gene in obese pediatric patients. Int J Pediatr Obes 6(2-2): e318-325.
  5. Salehi S, Emadi-Baygi M, Rezaei M, Kelishadi R, Nikpour P (2017) Identification of a new single-nucleotide polymorphism within the apolipoprotein a5 gene, which is associated with metabolic syndrome. Adv Biomed Res 6: 24.
  6. Bertoccini L, Sentinelli F, Incani M, Diego Bailetti, Flavia Agata Cimini et al. (2017) The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V. Lipids Health Dis 16: 179.
  7. Zhu WF, Wang CL, Liang L, Shen Z, Fu JF et al. (2014) Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents. Lipids Health Dis 13: 93.
  8. Luo G, Zheng L, Zhang X, Zhang J, Nilsson-Ehle P, et al. (2009) Genotyping of single nucleotide polymorphisms using base-quenched probe: a method does not invariably depend on the deoxyguanosine nucleotide. Anal Biochem 386(2): 161-166.
  9. Mao H, Luo G, Zhang J, Xu N (2018) Detection of simultaneous multimutations using base-quenched probe. Anal Biochem 543: 79-81.

© 2018 Guanghua Luo. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
Submit Query